Terms: = Prostate cancer AND ITK, PSCTK2, 3702, Q08881, ENSG00000113263, EMT, MGC126258, LYK, MGC126257 AND Prognosis
170 results:
1. Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.
Wu C; Zhu H; Zhang Y; Ding L; Wang J
PLoS One; 2024; 19(4):e0290753. PubMed ID: 38598542
[TBL] [Abstract] [Full Text] [Related]
2. Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.
Ashrafizadeh M; Zhang W; Tian Y; Sethi G; Zhang X; Qiu A
Cancer Metastasis Rev; 2024 Mar; 43(1):229-260. PubMed ID: 38374496
[TBL] [Abstract] [Full Text] [Related]
3. Co-expression of Twist and Snai1: predictor of poor prognosis and biomarker of treatment resistance in untreated prostate cancer.
Said R; Hernández-Losa J; Moline T; de Haro RSL; Zouari S; Blel A; Rammeh S; Derouiche A; Ouerhani S
Mol Biol Rep; 2024 Jan; 51(1):226. PubMed ID: 38281235
[TBL] [Abstract] [Full Text] [Related]
4. Harnessing function of emt in cancer drug resistance: a metastasis regulator determines chemotherapy response.
Ebrahimi N; Manavi MS; Faghihkhorasani F; Fakhr SS; Baei FJ; Khorasani FF; Zare MM; Far NP; Rezaei-Tazangi F; Ren J; Reiter RJ; Nabavi N; Aref AR; Chen C; Ertas YN; Lu Q
Cancer Metastasis Rev; 2024 Mar; 43(1):457-479. PubMed ID: 38227149
[TBL] [Abstract] [Full Text] [Related]
5. Dampened Regulatory Circuitry of TEAD1/ITGA1/ITGA2 Promotes TGFβ1 Signaling to Orchestrate prostate cancer Progression.
Cruz SP; Zhang Q; Devarajan R; Paia C; Luo B; Zhang K; Koivusalo S; Qin L; Xia J; Ahtikoski A; Vaarala M; Wenta T; Wei GH; Manninen A
Adv Sci (Weinh); 2024 Mar; 11(11):e2305547. PubMed ID: 38169150
[TBL] [Abstract] [Full Text] [Related]
6. Kinase D-interacting Substrate of 220 kDa Is Overexpressed in Gastric cancer and Associated With Local Invasion.
Cai S; Sun Z; Gao X; Ji KE; Ruge F; Shankla D; Liu X; Jiang WG; Ye L
Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):735-743. PubMed ID: 38035704
[TBL] [Abstract] [Full Text] [Related]
7. Synergistic effect of docetaxel combined with a novel multi-target inhibitor CUDC-101 on inhibiting human prostate cancer.
Li Z; Quan C; Li W; Ji M
Pathol Res Pract; 2023 Dec; 252():154938. PubMed ID: 37989076
[TBL] [Abstract] [Full Text] [Related]
8. New emerging targets in osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in carcinogenesis.
Sadrkhanloo M; Paskeh MDA; Hashemi M; Raesi R; Bahonar A; Nakhaee Z; Entezari M; Beig Goharrizi MAS; Salimimoghadam S; Ren J; Nabavi N; Rashidi M; Dehkhoda F; Taheriazam A; Tan SC; Hushmandi K
Pathol Res Pract; 2023 Nov; 251():154902. PubMed ID: 37922723
[TBL] [Abstract] [Full Text] [Related]
9. Bioinformatic Analysis of the CXCR2 Ligands in cancer Processes.
Korbecki J; Bosiacki M; Chlubek D; Baranowska-Bosiacka I
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686093
[TBL] [Abstract] [Full Text] [Related]
10. GLDC promotes colorectal cancer metastasis through epithelial-mesenchymal transition mediated by Hippo signaling pathway.
Yu H; Hu X; Zhang Y; Wang J; Ni Z; Wang Y; Zhu H
Med Oncol; 2023 Sep; 40(10):293. PubMed ID: 37668829
[TBL] [Abstract] [Full Text] [Related]
11. PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.
Rezaei S; Nikpanjeh N; Rezaee A; Gholami S; Hashemipour R; Biavarz N; Yousefi F; Tashakori A; Salmani F; Rajabi R; Khorrami R; Nabavi N; Ren J; Salimimoghadam S; Rashidi M; Zandieh MA; Hushmandi K; Wang Y
Eur J Pharmacol; 2023 Sep; 955():175909. PubMed ID: 37490949
[TBL] [Abstract] [Full Text] [Related]
12. Pro-tumorigenic role of lnc-ZNF30-3 as a sponge counteracting miR-145-5p in prostate cancer.
Le Hars M; Castro-Vega LJ; Rajabi F; Tabatadze D; Romero M; Pinskaya M; Groisman I
Biol Direct; 2023 Jul; 18(1):38. PubMed ID: 37434219
[TBL] [Abstract] [Full Text] [Related]
13. Biological and therapeutic viewpoints towards role of miR-218 in human cancers: Revisiting molecular interactions and future clinical translations.
Hashemi M; Gholami S; Raesi R; Sarhangi S; Mahmoodieh B; Koohpar ZK; Goharrizi MASB; Behroozaghdam M; Entezari M; Salimimoghadam S; Zha W; Rashidi M; Abdi S; Taheriazam A; Nabavi N
Cell Signal; 2023 Sep; 109():110786. PubMed ID: 37380085
[TBL] [Abstract] [Full Text] [Related]
14. STAT3 as a newly emerging target in colorectal cancer therapy: Tumorigenesis, therapy response, and pharmacological/nanoplatform strategies.
Hashemi M; Abbaszadeh S; Rashidi M; Amini N; Talebi Anaraki K; Motahhary M; Khalilipouya E; Harif Nashtifani A; Shafiei S; Ramezani Farani M; Nabavi N; Salimimoghadam S; Aref AR; Raesi R; Taheriazam A; Entezari M; Zha W
Environ Res; 2023 Sep; 233():116458. PubMed ID: 37348629
[TBL] [Abstract] [Full Text] [Related]
15. Six-transmembrane epithelial antigen of prostate 3 (STEAP3) is a potential prognostic biomarker in clear cell renal cell carcinoma that correlates with M2 macrophage infiltration and epithelial-mesenchymal.
Wei H; Li Z; Zhao Y; Zhu S; Wen S; Quan C
Cancer Rep (Hoboken); 2023 Aug; 6(8):e1824. PubMed ID: 37344930
[TBL] [Abstract] [Full Text] [Related]
16. Characterization of metabolism-associated molecular patterns in prostate cancer.
Yang B; Jiang Y; Yang J; Zhou W; Yang T; Zhang R; Xu J; Guo H
BMC Urol; 2023 Jun; 23(1):104. PubMed ID: 37280589
[TBL] [Abstract] [Full Text] [Related]
17. The Transcriptomic Profiles of
Olczak M; Orzechowska MJ; Bednarek AK; Lipiński M
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176106
[TBL] [Abstract] [Full Text] [Related]
18. FTO-stabilized miR-139-5p targets ZNF217 to suppress prostate cancer cell malignancies by inactivating the PI3K/Akt/mTOR signal pathway.
Azhati B; Reheman A; Dilixiati D; Rexiati M
Arch Biochem Biophys; 2023 Jun; 741():109604. PubMed ID: 37080415
[TBL] [Abstract] [Full Text] [Related]
19. Exploring the role of differentially expressed metabolic genes and their mechanisms in bone metastatic prostate cancer.
Zhang Q; Zhang P; Zhao Z; Wang J; Zhang H
PeerJ; 2023; 11():e15013. PubMed ID: 37070095
[TBL] [Abstract] [Full Text] [Related]
20. Exportin XPO7 acts as an oncogenic factor in prostate cancer via upregulation of TCF3.
Lin Y; Zhan M; Xu B
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7663-7677. PubMed ID: 37000263
[TBL] [Abstract] [Full Text] [Related]
[Next]
